Calcium Fructoborate (FruiteX-B®)

Evidence Level
Limited
2 Clinical Trials
5 Documented Benefits
2/5 Evidence Score

Calcium fructoborate (CFB), marketed as FruiteX-B® by VDF FutureCeuticals, is a patented complex of calcium, fructose, and boron designed to mimic the boron-carbohydrate complexes naturally found in plant foods such as fruits and vegetables. The published human research is small. One 14-day double-blind, placebo-controlled trial gave 110 mg twice daily to 60 adults with self-reported knee discomfort. Two other short double-blind studies measured only blood markers such as C-reactive protein, IL-6 and IL-1 beta, and one of those is described by its authors as a pilot study in middle-aged people already diagnosed with osteoarthritis. The author groups overlap across all three studies, and none of the published abstracts names the FruiteX-B brand; they describe calcium fructoborate generally. CFB supplies a small amount of boron, which should be counted toward the adult tolerable upper intake level of 20 mg of boron per day along with any other boron you take.

Studied Dose In the knee discomfort trial: 110 mg twice daily (about 220 mg a day, roughly 2 mg of boron) for 14 days. In the blood-marker study: 112 mg a day for 30 days. No study cited on this page ran longer than 30 days.
Active Compound Calcium fructoborate—a plant-mimetic complex of boron, fructose, and calcium delivering ~1.5–3 mg elemental boron per typical daily dose.

Benefits

Supports joint comfort

In one 14-day double-blind, placebo-controlled trial in 60 adults with self-reported knee discomfort, WOMAC and McGill Pain Questionnaire scores were lower at day 14. At day 7 the pain questionnaire had improved but the WOMAC change did not reach statistical significance. This is a single small, short study, so nothing is known about longer use. Joint pain that is persistent, severe or getting worse should be looked at by a healthcare provider.

Helps maintain healthy inflammation markers

Two short double-blind studies measured blood markers only and reported lower C-reactive protein and some cytokines compared with their starting values. These are laboratory numbers, not symptoms, and no cited study showed that the marker changes made anyone feel or function better.

Boron's role in mineral balance (background, not a tested benefit)

This is background nutrition science about boron in general: boron is involved in how the body handles calcium, magnesium and steroid hormones. None of the studies cited on this page measured bone density, bone markers or anything else about bone, so there is no direct evidence that calcium fructoborate benefits bone.

Supports cardiometabolic markers

The blood-marker studies also tracked total cholesterol, LDL and triglycerides alongside cytokines. Any changes were in lab values, over 30 days or less, in small groups, and no cited study followed heart health over time. These results should not be read as a heart benefit.

Low-dose, plant-mimetic boron source

Delivers boron in a complex resembling the boron-sugar structures found in plants, at an intake similar to what a fruit-rich diet provides. Count this boron toward the adult upper limit of 20 mg of boron a day if you also take other boron-containing supplements.

Mechanism of action

1

Cytokine modulation

Two short human studies tracked blood markers including CRP, IL-1 beta, IL-6 and MCP-1, and some of these were lower than at the start. That is a hypothesis about how CFB might act, not evidence that it changes any inflammation-related health outcome.

2

Boron-mediated enzyme support

General boron biology suggests boron interacts with enzymes involved in steroid-hormone metabolism, vitamin D handling and connective-tissue proteins. None of this was measured in the human calcium fructoborate studies cited on this page.

3

Mineral metabolism

Nutrition research on boron itself suggests it can influence how the kidneys handle calcium and magnesium. This is background on the mineral; the calcium fructoborate studies cited here did not measure mineral balance or bone.

4

Antioxidant signaling

Laboratory and animal work suggests boron-fructose complexes may affect the body's own antioxidant defenses. Test-tube and animal results do not automatically apply to people, and none of the human studies cited here measured antioxidant status.

Clinical trials

1
CFB for knee discomfort

Comparative double-blind, placebo-controlled trial, 110 mg CFB twice daily for 14 days

60 adults with self-reported knee discomfort, not a diagnosed joint disease

By day 14 the CFB group's WOMAC score fell by 13.73 points and the McGill Pain Questionnaire score by 8.9 points, both P<0.0001. At day 7 the WOMAC change was only -5.3 and did not reach statistical significance (P=0.06); only the McGill score did. The trial lasted 14 days in 60 people, so it says something about short-term self-reported discomfort and nothing about longer use.

2
CFB on inflammation and lipid markers

Double-blind, placebo-controlled trial, 112 mg/day CFB for 30 days

Adults with elevated inflammatory markers

Over 30 days the CFB group's CRP fell about 31%, IL-1 beta about 29% and MCP-1 about 31% compared with their own starting values. This study measured blood markers only. No pain, function or health outcome was recorded, so it does not demonstrate a benefit you would feel.

Side effects and drug interactions

Common Potential side effects

Reported as well tolerated in the cited studies, but those studies were small (the knee trial enrolled 60 people) and ran only 14 to 30 days; mild digestive upset has been reported.
Long-term safety is unknown: none of the studies cited on this page lasted longer than 30 days.
Adults have a tolerable upper intake level of 20 mg of boron a day. A typical CFB dose supplies only about 2 mg, but that boron counts toward the limit along with boron from other supplements and from food.
Not recommended during pregnancy at supplemental doses without medical supervision.
Allergic reactions are rare but possible in sensitive individuals.

Important Drug interactions

Estrogen-based therapies: some research on boron has reported modest increases in circulating estrogen. This was not tested in the calcium fructoborate studies cited here, so raise it with your prescriber.
Magnesium and calcium supplements: intakes add up across products, so check your daily totals if you take several mineral supplements.
Anticoagulants: no consistent interaction reported; monitor in high-risk patients.
Phosphate-binding medications: theoretical interaction via mineral metabolism.

Frequently asked questions about Calcium Fructoborate (FruiteX-B®)

What is Calcium Fructoborate?

Calcium fructoborate (CFB), marketed as FruiteX-B® by VDF FutureCeuticals, is a patented complex of calcium, fructose, and boron designed to mimic the boron-carbohydrate complexes naturally found in plant foods such as fruits and vegetables. The published human research is small.

What is Calcium Fructoborate used for?

Calcium Fructoborate is researched primarily for Joint Health and Anti-Inflammatory. In one 14-day double-blind, placebo-controlled trial in 60 adults with self-reported knee discomfort, WOMAC and McGill Pain Questionnaire scores were lower at day 14.

What is the recommended dosage of Calcium Fructoborate?

The clinically studied dose is In the knee discomfort trial: 110 mg twice daily (about 220 mg a day, roughly 2 mg of boron) for 14 days. In the blood-marker study: 112 mg a day for 30 days. No study cited on this page ran longer than 30 days. Always follow the product label and check with a healthcare provider for personal advice.

Is Calcium Fructoborate safe, and does it have side effects?

For most healthy adults, Calcium Fructoborate is well tolerated at studied doses. Reported effects can include: Reported as well tolerated in the cited studies, but those studies were small (the knee trial enrolled 60 people) and ran only 14 to 30 days; mild digestive upset has been reported. Long-term safety is unknown: none of the studies cited on this page lasted longer than 30 days. It may also interact with some medications. Calcium Fructoborate is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does Calcium Fructoborate interact with any medications?

Possible interactions include: Estrogen-based therapies: some research on boron has reported modest increases in circulating estrogen. This was not tested in the calcium fructoborate studies cited here, so raise it with your prescriber. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for Calcium Fructoborate?

NutraSmarts rates the evidence for Calcium Fructoborate as Limited (2 out of 5). It is backed by 2 clinical trials and 3 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(3 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Pietrzkowski Z, Phelan MJ, Keller R, Shu C, Argumedo R, Reyes-Izquierdo T. Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study. Clin Interv Aging. 2014;9:895-9. doi: 10.2147/CIA.S64590.PubMedUsed to support: Double-blind, placebo-controlled trial in 60 adults with self-reported knee discomfort. Over 14 days, 110 mg CFB twice daily lowered WOMAC (-13.73) and McGill Pain (-8.9) scores at day 14, both P<0.0001. At day 7 only the McGill score reached significance; the WOMAC change (-5.3) did not (P=0.06).
  2. Rogoveanu OC, Mogoşanu GD, Bejenaru C, Bejenaru LE, Croitoru O, Neamţu J, Pietrzkowski Z, Reyes-Izquierdo T, Biţă A, Scorei ID, Scorei RI. Effects of Calcium Fructoborate on Levels of C-Reactive Protein, Total Cholesterol, Low-Density Lipoprotein, Triglycerides, IL-1β, IL-6, and MCP-1: a Double-blind, Placebo-controlled Clinical Study. Biol Trace Elem Res. 2015;163(1-2):124-31. doi: 10.1007/s12011-014-0155-9.PubMedUsed to support: Double-blind, placebo-controlled study in which 112 mg/day CFB over 30 days was linked to roughly 31% lower CRP, 29% lower IL-1 beta and 31% lower MCP-1 versus each person's own baseline. It measured blood markers only (CRP, total cholesterol, LDL, triglycerides, IL-1 beta, IL-6 and MCP-1) and recorded no clinical outcome.
  3. Scorei R, Mitrut P, Petrisor I, Scorei I. A double-blind, placebo-controlled pilot study to evaluate the effect of calcium fructoborate on systemic inflammation and dyslipidemia markers for middle-aged people with primary osteoarthritis. Biol Trace Elem Res. 2011;144(1-3):253-63. doi: 10.1007/s12011-011-9083-0.PubMedUsed to support: Described by its authors as a pilot study, run in middle-aged people already diagnosed with primary osteoarthritis. It measured markers of systemic inflammation and blood lipids, not joint pain or joint function, so it does not show that CFB helps joints or the heart.